PBA
Paradigm Biocapital Advisors Portfolio holdings
AUM
$2.34B
This Quarter Return
+39.58%
1 Year Return
+13.3%
3 Year Return
+245.82%
5 Year Return
–
10 Year Return
–
AUM
$2.13B
AUM Growth
+$2.13B
(+46%)
Cap. Flow
+$302M
Cap. Flow
% of AUM
14.15%
Top 10 Holdings %
Top 10 Hldgs %
66.13%
Holding
36
New
6
Increased
15
Reduced
8
Closed
6
Top Buys
| 1 |
Nuvalent
NUVL
|
$163M |
| 2 |
Disc Medicine
IRON
|
$64.3M |
| 3 |
argenx
ARGX
|
$61.3M |
| 4 |
Ascendis Pharma
ASND
|
$44.3M |
| 5 |
Arcellx
ACLX
|
$39.2M |
Top Sells
| 1 |
United Therapeutics
UTHR
|
$69.4M |
| 2 |
Incyte
INCY
|
$52.7M |
| 3 |
Syndax Pharmaceuticals
SNDX
|
$34.7M |
| 4 |
TG Therapeutics
TGTX
|
$24.7M |
| 5 |
VRNA
Verona Pharma
VRNA
|
$15.1M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Nuvalent
NUVL
$5.52B
| $284M | 13.29% | 3,858,008 +2,219,861 | +136% | +$163M |
|
|
2
Arcellx
ACLX
$3.85B
| $203M | 9.51% | 3,658,624 +705,502 | +24% | +$39.2M |
|
|
3
argenx
ARGX
$43.6B
| $161M | 7.53% | 422,577 +161,134 | +62% | +$61.3M |
|
|
4
Disc Medicine
IRON
$2.07B
| $138M | 6.45% | 2,385,857 +1,113,578 | +88% | +$64.3M |
|
5
Legend Biotech
LEGN
$6.41B
| $114M | 5.34% | 1,894,644 -130,836 | -6% | -$7.87M |
|
6
Olema Pharmaceuticals
OLMA
$375M
| $111M | 5.19% | 7,903,600 +100,000 | +1% | +$1.4M |
|
7
Viridian Therapeutics
VRDN
$1.5B
| $104M | 4.89% | 4,794,488 +1,112,741 | +30% | +$24.2M |
|
8
Immunocore
IMCR
$1.62B
| $99.3M | 4.65% | 1,453,883 +69,197 | +5% | +$4.73M |
|
|
CERE
9
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $98.8M | 4.63% | 2,330,508 -202,464 | -8% | -$8.58M |
|
10
Xenon Pharmaceuticals
XENE
$2.98B
| $98M | 4.59% | 2,127,400 +635,565 | +43% | +$29.3M |
|
|
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $90.7M | 4.24% | 1,543,116 -125,000 | -7% | -$7.34M |
|
12
Crinetics Pharmaceuticals
CRNX
$2.92B
| $82.3M | 3.85% | 2,312,919 +134,182 | +6% | +$4.77M |
|
|
AUTL
13
Autolus Therapeutics
AUTL
$399M
| $81.2M | 3.8% | 12,611,335 -1,795,447 | -12% | -$11.6M |
|
|
BCYC
14
Bicycle Therapeutics
BCYC
$511M
| $67M | 3.14% | 3,707,001 +64,694 | +2% | +$1.17M |
|
|
AMAM
15
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $62M | 2.9% | 4,352,689 +864,093 | +25% | +$12.3M |
|
|
ALPN
16
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $60.5M | 2.83% | 3,176,743 +755,000 | +31% | +$14.4M |
|
|
17
Ascendis Pharma
ASND
$11.8B
| $44.3M | 2.07% | +351,700 | New | +$44.3M |
|
18
Arvinas
ARVN
$568M
| $38.3M | 1.79% | +931,303 | New | +$38.3M |
|
|
19
TG Therapeutics
TGTX
$4.65B
| $37.1M | 1.74% | 2,171,419 -1,447,596 | -40% | -$24.7M |
|
20
Zai Lab
ZLAB
$3.68B
| $29.8M | 1.4% | 1,091,779 -50,604 | -4% | -$1.38M |
|
21
Immatics
IMTX
$619M
| $22.5M | 1.05% | 2,136,339 +77,892 | +4% | +$820K |
|
22
Tarsus Pharmaceuticals
TARS
$2.47B
| $20.8M | 0.97% | +1,025,000 | New | +$20.8M |
|
|
CMPS
23
Compass Pathways
CMPS
$424M
| $19.8M | 0.93% | 2,265,988 +907,279 | +67% | +$7.94M |
|
24
Kura Oncology
KURA
$686M
| $18.2M | 0.85% | 1,262,828 +50,000 | +4% | +$719K |
|
25
Caribou Biosciences
CRBU
$174M
| $16.8M | 0.78% | 2,923,851 -20,662 | -0.7% | -$118K |
|